HCP, INC. Form 10-Q May 01, 2012 Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended March 31, 2012.

OR

0 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 1-08895

(Exact name of registrant as specified in its charter)

Maryland (State or other jurisdiction of incorporation or organization) **33-0091377** (I.R.S. Employer Identification No.)

3760 Kilroy Airport Way, Suite 300 Long Beach, CA 90806 (Address of principal executive offices)

(562) 733-5100 (Registrant s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES x NO o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). YES x NO o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer x

Non-accelerated Filer o (Do not check if a smaller reporting company) Accelerated Filer o

Smaller Reporting Company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) YES o NO x

As of April 25, 2012, there were 419,503,466 shares of the registrant s \$1.00 par value common stock outstanding.

INDEX

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements:	
	Condensed Consolidated Balance Sheets	3
	Condensed Consolidated Statements of Income	4
	Condensed Consolidated Statements of Comprehensive Income (Loss)	5
	Condensed Consolidated Statements of Equity	6
	Condensed Consolidated Statements of Cash Flows	7
	Notes to the Condensed Consolidated Financial Statements	8
<u>Item 2.</u>	Management s Discussion and Analysis of Financial Condition and Results of Operations	25
<u>Item 3.</u>	Quantitative and Qualitative Disclosures About Market Risk	38
<u>Item 4.</u>	Controls and Procedures	39
	PART II. OTHER INFORMATION	
Item 1A.	Risk Factors	39
<u>Item 2.</u>	Unregistered Sales of Equity Securities and Use of Proceeds	39
<u>Item 6.</u>	<u>Exhibits</u>	41
Signatures		42

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

(Unaudited)

	March 31, 2012	December 31, 2011
ASSETS		
Real estate:		
Buildings and improvements	\$ 8,974,639	\$ 8,933,278
Development costs and construction in progress	171,967	190,590
Land	1,729,560	1,729,677
Accumulated depreciation and amortization	(1,540,809)	(1,472,272)
Net real estate	9,335,357	9,381,273
Net investment in direct financing leases	6,768,111	6,727,777
Loans receivable, net	113,946	110,253
Investments in and advances to unconsolidated joint ventures	220,311	224,052
Accounts receivable, net of allowance of \$1,543 and \$1,341, respectively	24,381	26,681
Cash and cash equivalents	347,425	33,506
Restricted cash	45,458	41,553
Intangible assets, net	360,140	373,763
Real estate held for sale, net		4,159
Other assets, net	510,190	485,458
Total assets	\$ 17,725,319	\$ 17,408,475
LIABILITIES AND EQUITY		
Bank line of credit	\$	\$ 454,000
Senior unsecured notes	5,864,940	5,416,063
Mortgage debt	1,756,252	1,764,571
Other debt	86,734	87,985
Intangible liabilities, net	119,412	124,142
Accounts payable and accrued liabilities	519,492	275,478
Deferred revenue	68,527	65,614
Total liabilities	8,415,357	8,187,853
Commitments and contingencies		
Preferred stock, \$1.00 par value: aggregate liquidation preference of \$295.5 million as of		
December 31, 2011		285,173
Common stock, \$1.00 par value: 750,000,000 shares authorized; 419,433,018 and 408,629,444 shares issued and outstanding, respectively	419,433	408,629

408,629,444 shares issued and outstanding, respectively	419,433	408,629
Additional paid-in capital	9,776,708	9,383,536
Cumulative dividends in excess of earnings	(1,053,684)	(1,024,274)
Accumulated other comprehensive loss	(17,666)	(19,582)
Total stockholders equity	9,124,791	9,033,482
Joint venture partners	16,085	16,971
Non-managing member unitholders	169,086	170,169
Total noncontrolling interests	185,171	187,140

Total equity	9,309,962	9,220,622
Total liabilities and equity	\$ 17,725,319 \$	17,408,475

See accompanying Notes to Condensed Consolidated Financial Statements.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share data)

(Unaudited)

	Three Months Ended March 31, 2012 2011				
Revenues:					
Rental and related revenues	\$ 244,335	\$	253,081		
Tenant recoveries	22,650		23,444		
Resident fees and services	36,179		2,505		
Income from direct financing leases	154,535		13,395		
Interest income	819		38,096		
Investment management fee income	493		607		
Total revenues	459,011		331,128		
Costs and expenses:					
Interest expense	104,568		108,576		
Depreciation and amortization	88,241		91,182		
Operating	67,349		46,845		
General and administrative	20,102		21,952		
Total costs and expenses	280,260		268,555		
Other income, net	436		10,309		
Income before income taxes and equity income from unconsolidated joint ventures	179,187		72,882		
Income taxes	709		(37)		
Equity income from unconsolidated joint ventures	13,675		798		
Income from continuing operations	193,571		73,643		
Discontinued operations:					
Income before gain on sales of real estate, net of income taxes	137		341		
Gain on sales of real estate, net of income taxes	2,856				
Total discontinued operations	2,993		341		
Net income	196,564		73,984		
Noncontrolling interests share in earnings	(3,184)		(3,891)		
Net income attributable to HCP, Inc.	193,380		70,093		
Preferred stock dividends	(17,006)		(5,283)		
Participating securities share in earnings	(1,117)		(935)		
Net income applicable to common shares	\$ 175,257	\$	63,875		
Basic earnings per common share:					
Continuing operations	\$ 0.42	\$	0.17		
Discontinued operations	0.01				
Net income applicable to common shares	\$ 0.43	\$	0.17		
Diluted earnings per common share:					
Continuing operations	\$ 0.42	\$	0.17		
Discontinued operations	0.01				
Net income applicable to common shares	\$ 0.43	\$	0.17		

Weighted-average shares used to calculate earnings per common share:		
Basic	410,018	372,116
Diluted	411,661	373,960
Dividends declared per common share	\$ 0.50	\$ 0.48

See accompanying Notes to Condensed Consolidated Financial Statements.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In thousands)

(Unaudited)

		arch 31, 2011		
Net income	\$	196,564	\$	73,984
Other comprehensive income (loss), net of tax:				
Unrealized gains on securities		1,304		
Change in net unrealized gains (losses) on cash flow hedges:				
Unrealized gains		276		327
Reclassification adjustment realized in net income		89		(1,313)
Change in Supplemental Executive Retirement Plan obligation		45		34
Foreign currency translation adjustment		202		181
Total other comprehensive income (loss), net of tax		1,916		(771)
Total comprehensive income, net of tax		198,480		73,213
Total comprehensive income attributable to noncontrolling interest		(3,184)		(3,891)
Total comprehensive income attributable to HCP, Inc.	\$	195,296	\$	69,322

See accompanying Notes to Condensed Consolidated Financial Statements.

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(In thousands)

(Unaudited)

	Preferi	red Stock	Comm	on Stock	Additional Paid-In	Cumulative A Dividends In Excess Co	Accumulated Other omprehensiv&t	Total cockholdersNo	Total ncontrolling	Total
	Shares	Amount	Shares	Amount	Capital	Of Earnings In	. ,		Interests	Equity
January 1, 2012	11,820	\$ 285,173	408,629	\$ 408,629	\$ 9,383,536	\$ (1,024,274)	\$ (19,582)\$			
Net income Other						193,380		193,380	3,184	196,564
comprehensive income							1.916	1,916		1,916
Preferred stock							1,910	1,710		1,710
redemption	(11,820)	(285,173)				(11,723)		(296,896)		(296,896)
Issuance of	(,)	()				(;,-==)		(_, 0,0, 0)		()
common stock,										
net			9,559	9,559	358,397			367,956	(1,034)	366,922
Repurchase of										
common stock			(167)	(167) (6,817)		(6,984)		(6,984)
Exercise of stock										
options			1,412	1,412	36,219			37,631		37,631
Amortization of										
deferred					5 0 5 0			5 0 5 0		5 2 5 2
compensation					5,373			5,373		5,373
Preferred dividends						(5,283)		(5 202)		(5 292)
Common						(3,283)		(5,283)		(5,283)
dividends (\$0.50										
per share)						(205,784)		(205,784)		(205,784)
Distributions to						(203,701)		(205,701)		(200,701)
noncontrolling										
interests									(3,912)	(3,912)
Issuance of										
noncontrolling										
interests									181	181
Purchase of										
noncontrolling										
interests		<i>ф</i>	410 422	* 410 422	• • • • • • • • • • • • • • • • • • •		A 11 - 222 A	0.104.501 *	(388)	(388)
March 31, 2012		\$	419,433	\$ 419,433	\$ 9,776,708	\$ (1,053,684)	\$ (17,666)\$	9,124,791 \$	185,171 \$	9,309,962

						Cumulative Ac	cumulated			
					Additional	Dividends	Other	Total	Total	
	Prefer	red Stock	Comm	ion Stock	Paid-In	In Excess Con	nprehensives	tockholdersN	oncontrolling	Total
	Shares	Amount	Shares	Amount	Capital	Of EarningsInc	ome (Loss)	Equity	Interests	Equity
January 1, 2011	11,820	\$ 285,173	370,925	\$ 370,925	\$ 8,089,982	\$ (775,476)\$	(13,237)\$	7,957,367	\$ 188,680 \$	8,146,047
Net income						70,093		70,093	3,891	73,984
Other							(771)	(771)		(771)
comprehensive										

loss														
Issuance of														
common stock, net				35,200		35,200		1,217,165				1,252,365		1,252,365
Repurchase of														
common stock				(122)		(122))	(4,355)	1			(4,477)		(4,477)
Exercise of stock														
options				6		6		155				161		161
Amortization of														
deferred														
compensation								5,102				5,102		5,102
Preferred														
dividends									(5	,283)		(5,283)		(5,283)
Common														
dividends (\$0.48														
per share)									(178	,926)		(178,926)		(178,926)
Distributions to														
noncontrolling													(2) ((7)	
interests													(3,667)	(3,667)
Noncontrolling														
interest in acquired													1 500	1 500
assets Purchase of													1,500	1,500
noncontrolling								(18,098)				(10,000)	(489)	(10 507)
interests Moreh 31 2011	11,820	\$	285,173	406,009	¢	406.000	¢	())		502) ¢	(14.009) ¢	(18,098)	~ /	(18,587)
March 31, 2011	11,820	Ф	203,173	400,009	Ф	400,009	Ф	9,289,931	\$ (009	,592)\$	(14,008)\$	9,077,533 \$	109,913 \$	9,207,448

See accompanying Notes to Condensed Consolidated Financial Statements.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands) (Unaudited)

Cash Iows from operating activities: Note income S 196,564 S 73,984 Adjustments to reconcile net income to net cash provided by operating activities: Note 100 Note 100 Note 100 Depreciation and amortization of real estate, in-place lease and other intangibles: S8,241 91,182 Discontinued operations 88,241 91,182 Discontinued operations 5,573 5,102 Amortization of advere and below market lease intangibles, net (697) (006) Amotrization of deferred financing costs, net 4,529 14,944 Straight-line rents (9,927) (17,300) Loan and direct financing costs, net (25,878) (19,969) Equity income from unconsolidated joint ventures 913 332 Gain on sales of real estate (2,875) (798) Gain upon consolidation of joint venture (8,039) (2,877) Accounts receivable, net 2,300 4,416 Other acets (7,877) 8,073 Accounts receivable, net (2,2,40) (6,438) Net cash prorided by operating activities (7,877) </th <th></th> <th colspan="5">Three Months Ended March 31, 2012 2011</th>		Three Months Ended March 31, 2012 2011				
Adjustments to reconcile net income to net cash provided by operating activities: Pereciation and amortization of real estate, in-place lease and other intangibles: Continuing operations 88,241 91,182 Discontinued operations 35 238 Amortization of above and below market lease intangibles, net (697) (0906) Amortization of deferred financing costs, net 4,529 14,948 Straight-line rents (9,927) (17,300) Loan and direct financing lease interest accretion (25,878) (19,969) Deferred rental revenues 1,839 1,116 Equity income from unconsolidated joint ventures 913 332 Gain on sales of real estate (2,856) (8,039) Gain upon consolidation of joint venture (8,039) (2,113) Changes in: 203 (2,113) Accounts provided by operating activities (36,060) (4416) Other assets (2,360) 44216 Accounts purple and accrued liabilities (52,619) (4292) Cash toxs from investing activities (36,060) (4983) Protecids from sales of real estate, net (7,277) 8,073 Ac	Cash flows from operating activities:					
Depreciation and amoritzation of real estate, in-place lease and other intangibles: 88,241 91,182 Discontinued operations 35 238 Amoritzation of above and below market lease intangibles, net (697) (906) Amoritzation of deferred compensation 5,373 5,102 Amoritzation of deferred financing costs, net 4,529 114,948 Straight-line rents (9927) (17,300) Loan and direct financing costs, net 1,839 1,106 Equity incomes from unconsolidated joint ventures (13,675) (798) Distributions of eral estate (2,856) (2,815) Gain on sales of real estate (2,815) (2,113) Changes in: 2,300 (4,416) Accounts receivable, net 2,300 (4,416) Other asets (7,877) 8,073 Accounts payable and accrued liabilities (52,619) (4292) Net cash provided by operating activities 186,468 149,827 Cash used in the HCP Ventures II purchase, net of cash acquired (2,340) (65,453) Leash used in the HCP Ventures II purchase, net of cash acquire		\$ 196,564	\$	73,984		
Continuing operations88,24191,182Discontinued operations35238Amortization of above and below market lease intangibles, net(697)(0906)Amortization of deferred financing costs, net4,52914,948Straight-line rents(9,927)(17,300)Loan and direct financing lease interest accretion(25,878)(19,969)Deferred rental revenues1,8591,106Equity income from unconsolidated joint ventures(13,675)(7989)Distributions of carnings from unconsolidated joint ventures(23,878)(20,909)Chain and set of real estate(23,00)4,416Other assets(23,00)4,416(13,600)Chain ages in:203(2,113)(429)Accounts receivable, net(2,340)(429)(429)Accounts receivable, net(22,340)(65,453)(249)Cash used in the HCP Ventures II purchase, net of cash acquired(22,340)(65,453)Leasing costs and tenant and capital improvements(8,931)(9,493)Proceeds from sales of real estate, net7,238(31,146)Distributions in excess of earnings from unconsolidated joint ventures(31,146)(57,503)Cash used in investing activities(31,146)(57,503)Increase in restricted cash(30,00)(4,16)Distributions in excess of comings from unconsolidated joint ventures(31,46)Distributions in excess of comings from unconsolidated joint ventures(31,46)Distributions in excess of comings from unconsolid						
Discontinued operations 35 238 Amortization of above and below market lease intangibles, net (607) (906) Amortization of deferred financing costs, net 4,529 14,948 Straight-line rents (9,927) (17,300) Loan and direct financing lease interest accretion (25,878) (19,969) Deferred rental revenues (13,675) (798) Gain on soles of real estate (23,675) (298) Gain on soles of real estate (23,66) (24,13) Changes in (23,60) (24,13) Accounts receivable, net 2,300 4,416 Other assets (7,877) 8,073 Accounts receivable, net (23,61) (429) Other assets (7,877) 8,073 Cash provided by operating activities (13,6060) (13,6060) Cash used in the HCP Ventures II purchase, net of cash acquired (13,6060) (04,93) Proceeds from ales of real estate, net 7,238 (13,6060) Cash used in the HCP Ventures II purchase, net of cash acquired (13,6060) (5,738)						
Amonization of above and below market lease intangibles, net(697)(906)Amonization of deferred financing costs, net4,52914,948Straight-line rents(9,927)(17,300)Loan and direct financing lease interest accretion(25,878)(19,969)Deferred rental revenues1,8391,106Equity income from unconsolidated joint ventures(13,675)(798)Distributions of earnings from unconsolidated joint ventures(2,856)(8,039)Derivative (gains) losses, net203(2,113)Changes in:203(2,113)Accounts receivable, net(3,300)(4,416Other assets(7,877)8,073Accounts receivable, net(13,666)(429)Net cash provided by operating activities186,468149,827Cash flows from investing activities(13,660)(13,660)Other acquisitions and development of real estate(2,340)(65,453)Leasing costs and tenant and capital improvements(8,931)(9,493)Proceeds from sales of real estate, net7,238(3,905)Distributions in excess of earnings from unconsolidated joint ventures(3,905)(5,738)Increase in subtrict cash(3,905)(5,738)(9,493)Proceeds from sales of real estate, net(3,905)(5,738)Increase in subtrict cash(3,905)(5,738)(2,113)Increase in subtrict cash(3,905)(5,738)(2,113)Increase in subtrict cash(3,905)(5,738)(2,130)Distri)		,		
Amortization of deferred compensation 5,73 5,102 Amortization of deferred financing costs, net 4,529 14,948 Straight-line rents (9,927) (17,300) Loan and direct financing lease interest accretion (25,878) (19,969) Deferred rental revenues (13,675) (798) Deferred rental revenues (13,675) (798) Distributions of earnings from unconsolidated joint ventures (13,675) (798) Gain on sales of real estate (2,856) (2,856) Gain on sales of real estate (2,130) (4,116) Changes in: - - (8,039) Derivative (gains) losses, net 2,300 4,416 (4,29) Net cash provided by operating activities (13,600) (4,29) (4,29) Net cash provided by operating activities (13,600) (6,543) (9,493) Other ascet in the HCP Ventures II purchase, net of cash acquired (13,000) (65,453) Leasing costs and tenant and capital improvements (8,931) (9,493) Proceeds from sales of real estate, net 7,238 (13,005)<						
Amotization of deferred financing costs, net $4,529$ $14,948$ Straight-line rents(9,927)(17,300)Loan and direct financing lease interest accretion(25,878)(19,969)Deferred rental revenues1,8391,106Equity income from unconsolidated joint ventures(13,675)(798)Distributions of earnings from unconsolidated joint ventures913332Gain on sales of real estate(2,856)(8,039)Derivative (gains) losses, net203(2,113)Changes in:2,3004,416Other assets(7,877)8,073Accounts receivable, net(2,2619)(429)Net cash provided by operating activities186,468149,827Cash lows from investing activities(13,660)(13,660)Other assets and accrued liabilities(2,240)(65,453)Leasing costs and tenant and capital improvements(8,231)(9,493)Proceeds from sales of real estate, net7,238(11,660)Distributions in excess of earnings from unconsolidated joint ventures2,716637Principal repayments on loans receivable4,015287Investments in loans receivable(3,905)(5,738)Increase in restricted cash(39,05)(5,738)Increase in restricted cash(3,905)(5,738)Increase in estricted cash(3,905)(5,738)Increase in contraing activities(10,057)(21,137)Issuance of senior unsecured notes4,50,0002,400,000Deferred financin		()		()		
Straight-line rents(9927)(17,300)Loan and direct financing lease interest accretion(25,878)(19,969)Deferred rental revenues1,8391,106Equity income from unconsolidated joint ventures(13,675)(798)Distributions of earnings from unconsolidated joint ventures913332Gain on sales of real estate(2,856)(8,039)Derivative (gains) losses, net203(2,113)Changes in:2,3004,416Accounts receivable, net2,3004,416Other assets(7,877)8,073Accounts payable and acrued liabilities(52,619)(429)Net cash provided by operating activities:136,6468149,827Cash flows from investing activities136,6660(65,453)Cash flows from investing activities(13,6060)(65,453)Other acquisitions and development of real estate(22,340)(65,453)Leasing costs and tenant and capital improvements(8,931)(9,493)Proceeds from sales of real estate, net7,23810Distributions in excess of earnings from unconsolidated joint ventures2,716637Investments in loans receivable(3,905)(5,738)Net cash used in investing activities(3,905)(5,738)Increase in restricted cash(3,905)(5,738)Net cash used in investing activities(13,146)(57,503)Cash duse from financing activities(13,177)(4,852)Net repayments of nontage debt(10,057)(21,137)		,		,		
Loan and direct financing lease interest accretion $(25,878)$ $(19,969)$ Deferred rental revenues $1,839$ $1,106$ Equity income from unconsolidated joint ventures 913 332 Gain on sales of real estate $(2,856)$ $(8,039)$ Derivative (gains) losses, net 203 $(2,113)$ Changes in: 2330 $4,416$ Other assets $(7,877)$ $8,073$ Accounts receivable, net $2,300$ $4,416$ Other assets $(7,877)$ $8,073$ Accounts receivable and accrued liabilities $(52,619)$ (429) Net cash provided by operating activities $(136,060)$ $(136,060)$ Cash used in the HCP Ventures II purchase, net of cash acquired $(136,060)$ $(136,060)$ Other acquisitions and development of real estate $(22,340)$ $(65,453)$ Leasing costs and tenant and capital improvements $8,931$ $(9,493)$ Principal repayments on loans receivable 4015 287 Investments in loans receivable $(9,939)$ $(55,738)$ Increase in restricted cash $(3,0,05)$ $(5,738)$ Net cash used in investing activities $(3,1,146)$ $(57,538)$ Cash used in investing activities $(10,057)$ $(2,1,17)$ Isstance of senior unscured notes 4015 287 Investments in loans receivable $(9,939)$ $(55,63)$ Investments in loans receivable $(9,939)$ $(55,738)$ Net cash used in investing activities $(3,1,146)$ $(57,538)$ Net cash used in investing	Amortization of deferred financing costs, net					
Deferred rental revenues1,8391,106Equity income from unconsolidated joint ventures(13,675)(798)Distributions of earnings from unconsolidated joint ventures913332Gain on sales of real estate(2,856)(8,039)Gain upon consolidation of joint venture(8,039)(2,113)Changes in:2,3004,416Accounts receivable, net2,3004,416Other assets(7,877)8,073Accounts payable and accrued liabilities(52,619)(429)Net cash provided by operating activities(136,060)(156,060)Other assets(2,340)(65,453)(9,493)Proteceds from all estate, net of cash acquired(136,060)(16,943)(9,493)Proceeds from sales of real estate, net7,238(2,340)(65,453)Increase in excuss of earnings from unconsolidated joint ventures2,716637Principal repayments on loans receivable(9,939)(359,683)Increase in restricted cash(3,905)(5,738)Increase in in investing activities(31,146)(575,503)Cash flows from financing activities(10,057)(21,137)Issuance of senior unsecured notes450,0002,400,000Defered refer financing costs(10,117)(42,852)Net repayments of mortage debt(10,057)(21,137)Issuance of senior unsecured notes397,5591,248,049Dividends paid on common and preferred stock(21,1067)(11,42,052)Issuance of unorunoning interests<						
Equity income from unconsolidated joint ventures $(13,675)$ (798) Distributions of earnings from unconsolidated joint ventures913332Gain on sales of real estate $(2,856)$ Gain on sales of real estate $(2,856)$ Changes in:203 $(2,113)$ Accounts receivable, net $2,300$ $4,416$ Other assets $(7,877)$ $8,073$ Accounts payable and accrued liabilities $(52,619)$ (429) Net cash provided by operating activities $(186,468)$ $149,827$ Cash flows from investing activities $(136,660)$ $(136,660)$ Other assets and teaptat improvements $(8,931)$ $(9,493)$ Proceeds from sales of real estate, net $7,238$ $7,238$ Distributions in excess of earnings from unconsolidated joint ventures $2,716$ 637 Principal repayments no loans receivable $(3,905)$ $(5,738)$ Investments in loans receivable $(3,905)$ $(5,738)$ Investments in loans receivable $(10,057)$ $(21,137)$ Investments in loans receivable $(10,017)$ $(21,137)$ Isstance of senior unsecured notes $450,000$ $2,400,000$ Defered financing activities: $(10,117)$ $(42,829)$ Net repayments under bark line of credit $(25,030)$ $(24,000)$ Repayments of morting activities: $(10,117)$ $(42,829)$ Net repayments under bark line of credit $(25,030)$ $(24,000)$ Defered financing activities $(31,146)$ $(57,503)$ Net repayments under bark	Loan and direct financing lease interest accretion	(25,878)		(19,969)		
Distributions of earnings from unconsolidated joint ventures 913 332 Gain on sales of real estate (2,856) (8,039) Derivative (gains) losses, net 203 (2,113) Changes in: 2,300 4,416 Other assets (7,877) 8,073 Accounts receivable, net (2,2,619) (429) Net cash provided by operating activities (8,031) (9,432) Cash flows from investing activities (136,060) (52,619) (452) Other assets (8,931) (9,433) (2,434) (65,453) Leasing costs and tenant and capital improvements (8,931) (9,493) (65,453) Proceeds from sales of real estate, net 7,238 (136,060) (136,060) Distributions in excess of earnings from unconsolidated joint ventures 2,716 637 Principal repayments on loans receivable (0,15) 287 Investments in loans receivable (9,393) (55,783) Increase in restricted cash (3,905) (5,738) Net ash used in investing activities (11,14) (55,503)		1,839		1,106		
Gain on sales of real estate $(2,856)$ Gain upon consolidation of joint venture (8.039) Derivative (gains) losses, net 203 $(2,113)$ Changes in: $2,300$ 4.416 Other assets $(7,877)$ 8.073 Accounts payable and accrued liabilities $(52,619)$ (429) Net cash provided by operating activities $186,468$ $149,827$ Cash flows from investing activities $(136,060)$ $(136,060)$ Other acquisitions and development of real estate $(22,340)$ $(65,453)$ Leasing costs and tenant and capital improvements $(8,931)$ (9.493) Proceeds from sales of real estate, net 7.238 7.238 Distributions in excess of earnings from unconsolidated joint ventures $2,716$ 637 Principal repayments on loans receivable $(9,939)$ $(359,683)$ Increase in restricted cash $(3,905)$ $(57,503)$ Cash lused in investing activities: $(11,067)$ $(21,137)$ Issuance of senior unscured notes $450,000$ $2,400,000$ Deferred financing costs $(10,057)$ $(21,137)$ Issuance of senior unscured notes $397,569$ $1,248,049$ Dividends paid on common and preferred stock $(211,067)$ $(18,209)$ Issuance of noncontrolling interests $313,919$ $2,951,921$ Net cash nordand preferred stock $(31,140)$ $(3,57,57)$ Net increase in cash and cash equivalents, beginning of period $33,506$ $1,035,701$				(798)		
Gain upon consolidation of joint venture(8,039)Derivative (gains) losses, net203(2,113)Changes in:2,3004,416Accounts receivable, net2,3004,416Other assets(7,877)8,073Accounts payable and accrued liabilities(52,619)(429)Net cash provided by operating activities(86,468149,827Cash lows from investing activities(136,060)(05,453)Cher acquisitions and development of real estate(22,340)(65,453)Leasing costs and tenant and capital improvements(8,931)(9,493)Proceeds from sales of real estate, net7,238(136,060)Distributions in excess of earnings from unconsolidated joint ventures2,716637Principal repayments on loans receivable4,015287Investments in loans receivable(3,905)(57,503)Net cash used in investing activities(31,146)(575,503)Cash used in investing activities(31,146)(575,503)Net cash used in investing activities(10,057)(21,137)Issuance of senior unscured notes450,0002,400,000Deferred financing costs(10,117)(42,852)Net proceeds from the issuance of common stock and exercise of options397,5691,248,049Issuance (purchase) of noncontrolling interests(3,912)(3,667)Net proceeds from the issuance of common stock and exercise of options181(18,587)Net proceeds from the issuance of common stock and exercise of options181(18	Distributions of earnings from unconsolidated joint ventures	913		332		
Derivative (gains) losses, net 203 (2,113) Changes in:	Gain on sales of real estate	(2,856)				
Changes in: Changes in: Accounts receivable, net 2,300 4,416 Other assets (7,877) 8,073 Accounts payable and accrued liabilities (52,619) (429) Net cash provided by operating activities 186,468 149,827 Cash lows from investing activities (136,060) (136,060) Other acquisitions and development of real estate (22,340) (65,453) Leasing costs and tenant and capital improvements (8,931) (9,493) Proceeds from sales of real estate, net 7,238 0 Distributions in excess of earnings from unconsolidated joint ventures 2,716 637 Principal repayments on loans receivable 4,015 287 Investments in loans receivable (9,939) (559,683) Increase in restricted cash (3,146) (57,503) Set cash used in investing activities (3,1146) (57,503) Ret payments under bank line of credit (454,000) 2,400,000 Repayments of mortage debt (10,057) (2,1,37) Issuance of senior unsecured notes 397,569 1,248,049	Gain upon consolidation of joint venture			(8,039)		
Accounts receivable, net2,3004,416Other assets $(7,877)$ 8,073Accounts payable and accrued liabilities $(52,619)$ (429) Net cash provided by operating activities186,468149,827 Cash flows from investing activities 186,468149,827Cash used in the HCP Ventures II purchase, net of cash acquired $(22,340)$ $(65,453)$ Leasing costs and tenant and capital improvements $(8,931)$ $(9,493)$ Proceeds from sales of real estate, net $7,238$ $7,238$ Distributions in excess of earnings from unconsolidated joint ventures $2,716$ 637 Principal repayments no loans receivable $4,015$ 287 Investments in loans receivable $(9,939)$ $(359,683)$ Increase in restricted cash $(3,905)$ $(5,738)$ Net cash used in investing activities $(31,146)$ $(575,503)$ Net repayments under bank line of credit $(454,000)$ $2,400,000$ Deferred financing costs $(10,117)$ $(42,852)$ Net proceeds from the issuance of common stock and exercise of options $397,569$ $1,248,049$ Dividends paid on common and preferred stock $(211,067)$ $(184,209)$ Issuance (purchase) of noncontrolling interests 181 $(184,587)$ Distributions to noncontrolling interests $33,919$ $2,951,921$ Cash nord acash equivalents $33,506$ $1,036,701$	Derivative (gains) losses, net	203		(2,113)		
Other assets(7,877)8,073Accounts payable and accrued liabilities(52,619)(429)Net cash provided by operating activities186,468149,827 Cash flows from investing activities (136,060)(136,060)Other acquisitions and development of real estate(22,340)(65,453)Leasing costs and tenant and capital improvements(8,931)(9,939)Proceeds from sales of real estate, et7,2380Distributions in excess of earnings from unconsolidated joint ventures2,716637Principal repayments on loans receivable4,015287Investments in loans receivable(3,905)(5,738)Net cash used in investing activities(31,146)(575,503) Cash flows from financing activities (10,057)(21,137)Issuance of senior unsecured notes450,0002,400,000Peferred financing costs(10,117)(42,852)Net proceeds from the issuance of common stock and exercise of options397,5691,248,049Dividends paid on common and preferred stock(211,067)(184,209)Issuance (purchase) of noncontrolling interests(3,912)(3,667)Net nonecontrolling interests(3,912)(3,667)Dividends paid on common and preferred stock(3,912)(3,667)Net cash provided by financing activities181(18,587)Divitibutions to noncontrolling interests(3,912)(3,667)Net cash and cash equivalents, beginning of period33,5061,036,701	Changes in:					
Accounts payable and accrued liabilities $(52,619)$ (429) Net cash provided by operating activities186,468149,827 Cash flows from investing activities (136,060)(136,060)Cash used in the HCP Ventures II purchase, net of cash acquired $(22,340)$ $(65,453)$ Leasing costs and tenant and capital improvements $(8,931)$ $(9,493)$ Proceeds from sales of real estate, net $7,238$ $7,238$ Distributions in excess of earnings from unconsolidated joint ventures $2,716$ 637 Principal repayments on loans receivable $(9,939)$ $(359,683)$ Increase in restricted cash $(3,905)$ $(5,738)$ Net cash used in investing activities $(454,000)$ Repayments on doter bank line of credit $(454,000)$ Repayments on doter bank line of credit $(10,057)$ $(21,137)$ Issuance of senior unsccured notes $397,569$ $1,248,049$ Dividends paid on common stock and exercise of options $397,569$ $1,248,049$ Dividends paid on common and preferred stock $(211,067)$ $(184,209)$ Issuance (purchase) of noncontrolling interests 181 $(18,587)$ Divitionus to noncontrolling interests $33,506$ $1,036,701$ Net cash and cash equivalents $31,3919$ $2,951,921$ Cash and cash equivalents, beginning of period $33,506$ $1,036,701$	Accounts receivable, net	2,300		4,416		
Net cash provided by operating activities 148,468 149,827 Cash lows from investing activities: (136,060) Other acquisitions and development of real estate (22,340) (65,453) Leasing costs and tenant and capital improvements (8,931) (9,493) Proceeds from sales of real estate, net 7,238 (11,01,01,01,01,01,01,01,01,01,01,01,01,0	Other assets	(7,877)		8,073		
Cash flows from investing activities:Cash used in the HCP Ventures II purchase, net of cash acquired(136,060)Other acquisitions and development of real estate(22,340)(65,453)Leasing costs and tenant and capital improvements(8,931)(9,493)Proceeds from sales of real estate, net7,238Distributions in excess of earnings from unconsolidated joint ventures2,716637Principal repayments on loans receivable4,015287Investments in loans receivable(9,939)(359,683)Increase in restricted cash(31,146)(575,503)Net cash used in investing activities(31,146)(575,503)Cash flows from financing activities(10,057)(21,137)Issuance of senior unsecured notes450,0002,400,000Deferred financing costs(10,117)(42,852)Net proceeds from the issuance of common stock and exercise of options397,5691,248,049Dividends paid on common and preferred stock(211,067)(184,209)Issuance (purchase) of noncontrolling interests181(18,587)Distributions to noncontrolling interests313,9192,951,921Cash and cash equivalents313,3061,036,701	Accounts payable and accrued liabilities	(52,619)		(429)		
Cash used in the HCP Ventures II purchase, net of cash acquired(136,060)Other acquisitions and development of real estate(22,340)(65,453)Leasing costs and tenant and capital improvements(8,931)(9,493)Proceeds from sales of real estate, net7,2381000000000000000000000000000000000000	Net cash provided by operating activities	186,468		149,827		
Other acquisitions and development of real estate $(22,340)$ $(65,453)$ Leasing costs and tenant and capital improvements $(8,931)$ $(9,493)$ Proceeds from sales of real estate, net $7,238$ Distributions in excess of earnings from unconsolidated joint ventures $2,716$ 637 Principal repayments on loans receivable $(9,939)$ $(359,683)$ Investments in loans receivable $(9,939)$ $(359,683)$ Increase in restricted cash $(3,905)$ $(5,738)$ Net cash used in investing activities $(31,146)$ $(575,503)$ Cash flows from financing activities: $(10,057)$ $(21,137)$ Net repayments of mortgage debt $(10,057)$ $(21,137)$ Issuance of senior unsecured notes $450,000$ $2,400,000$ Deferred financing costs $(10,117)$ $(42,852)$ Net proceeds from the issuance of common stock and exercise of options $397,569$ $1,248,049$ Dividends paid on common and preferred stock $(211,067)$ $(184,209)$ Issuance (purchase) of noncontrolling interests $(3,912)$ $(3,667)$ Net cash provided by financing activities $158,597$ $3,377,597$ Net increase in cash and cash equivalents $313,919$ $2,951,921$ Cash and cash equivalents, beginning of period $33,506$ $1,036,701$	Cash flows from investing activities:					
Leasing costs and tenant and capital improvements $(8,931)$ $(9,493)$ Proceeds from sales of real estate, net7,238Distributions in excess of earnings from unconsolidated joint ventures2,716637Principal repayments on loans receivable4,015287Investments in loans receivable $(9,939)$ $(359,683)$ Increase in restricted cash $(3,905)$ $(5,738)$ Net cash used in investing activities $(31,146)$ $(575,503)$ Net repayments under bank line of credit $(454,000)$ $(10,057)$ $(21,137)$ Issuance of senior unsecured notes450,0002,400,000Deferred financing costs $(10,117)$ $(42,852)$ Net proceeds from the issuance of common stock and exercise of options397,569 $1,248,049$ Dividends paid on common and preferred stock $(211,067)$ $(184,209)$ Issuance (purchase) of noncontrolling interests $(3,912)$ $(3,667)$ Net cash provided by financing activities $(3,912)$ $(3,912)$ Distributions to noncontrolling interests $(313,919)$ $(2,951,921)$ Cash and cash equivalents, beginning of period $33,506$ $1,036,701$	Cash used in the HCP Ventures II purchase, net of cash acquired			(136,060)		
Proceeds from sales of real estate, net7,238Distributions in excess of earnings from unconsolidated joint ventures2,716637Principal repayments on loans receivable4,015287Investments in loans receivable(9,939)(359,683)Increase in restricted cash(3,905)(5,738)Net cash used in investing activities(3,905)(5,75,03)Cash flows from financing activities:(454,000)Repayments of mortgage debt(10,057)(21,137)Issuance of senior unsecured notes450,0002,400,000Deferred financing costs(10,117)(42,852)Net proceeds from the issuance of common stock and exercise of options397,5691,248,049Dividends paid on common and preferred stock(211,067)(184,209)Issuance (purchase) of noncontrolling interests(3,912)(3,667)Net cash provided by financing activities158,5973,377,597Net cash provided by financing activities313,9192,951,921Cash and cash equivalents, beginning of period33,5061,036,701	Other acquisitions and development of real estate	(22,340)		(65,453)		
Distributions in excess of earnings from unconsolidated joint ventures2,716637Principal repayments on loans receivable4,015287Investments in loans receivable(9,939)(359,683)Increase in restricted cash(3,905)(5,738)Net cash used in investing activities(31,146)(575,503)Cash flows from financing activities:Net repayments under bank line of credit(454,000)Repayments of mortgage debt(10,057)(21,137)Issuance of senior unsecured notes450,0002,400,000Deferred financing costs(10,117)(42,852)Net proceeds from the issuance of common stock and exercise of options397,5691,248,049Dividends paid on common and preferred stock(211,067)(18,209)Issuance (purchase) of noncontrolling interests181(18,587)Distributions to noncontrolling interests(3,912)(3,667)Net cash provided by financing activities313,9192,951,921Cash and cash equivalents, beginning of period33,5061,036,701	Leasing costs and tenant and capital improvements	(8,931)		(9,493)		
Principal repayments on loans receivable4,015287Investments in loans receivable(9,939)(359,683)Increase in restricted cash(3,905)(5,738)Net cash used in investing activities(31,146)(575,503)Cash flows from financing activities:Net repayments under bank line of credit(454,000)Repayments of mortgage debt(10,057)(21,137)Issuance of senior unsecured notes450,0002,400,000Deferred financing costs(10,117)(42,852)Net proceeds from the issuance of common stock and exercise of options397,5691,248,049Dividends paid on common and preferred stock(211,067)(184,209)Issuance (purchase) of noncontrolling interests181(18,587)Distributions to noncontrolling interests(3,912)(3,667)Net cash provided by financing activities313,9192,951,921Cash and cash equivalents, beginning of period33,5061,036,701	Proceeds from sales of real estate, net	7,238				
Investments in loans receivable(9,939)(359,683)Increase in restricted cash(3,905)(5,738)Net cash used in investing activities(31,146)(575,503) Cash flows from financing activities: (454,000)Repayments under bank line of credit(454,000)Repayments of mortgage debt(10,057)(21,137)Issuance of senior unsecured notes450,0002,400,000Deferred financing costs(10,117)(42,852)Net proceeds from the issuance of common stock and exercise of options397,5691,248,049Dividends paid on common and preferred stock(211,067)(184,209)Issuance (purchase) of noncontrolling interests181(18,587)Distributions to noncontrolling interests158,5973,377,597Net cash provided by financing activities158,5973,377,597Net increase in cash and cash equivalents313,9192,951,921Cash and cash equivalents, beginning of period33,5061,036,701	Distributions in excess of earnings from unconsolidated joint ventures	2,716		637		
Increase in restricted cash(3,905)(5,738)Net cash used in investing activities(31,146)(575,503) Cash flows from financing activities: (10,057)(21,137)Net repayments under bank line of credit(454,000)Repayments of mortgage debt(10,057)(21,137)Issuance of senior unsecured notes450,0002,400,000Deferred financing costs(10,117)(42,852)Net proceeds from the issuance of common stock and exercise of options397,5691,248,049Dividends paid on common and preferred stock(211,067)(184,209)Issuance (purchase) of noncontrolling interests181(18,587)Distributions to noncontrolling interests(3,912)(3,667)Net cash provided by financing activities158,5973,377,597Net increase in cash and cash equivalents313,9192,951,921Cash and cash equivalents, beginning of period33,5061,036,701	Principal repayments on loans receivable	4,015		287		
Net cash used in investing activities(31,146)(575,503)Cash flows from financing activities:(454,000)Net repayments under bank line of credit(454,000)Repayments of mortgage debt(10,057)(21,137)Issuance of senior unsecured notes450,0002,400,000Deferred financing costs(10,117)(42,852)Net proceeds from the issuance of common stock and exercise of options397,5691,248,049Dividends paid on common and preferred stock(211,067)(184,209)Issuance (purchase) of noncontrolling interests181(18,587)Distributions to noncontrolling interests(3,912)(3,667)Net cash provided by financing activities158,5973,377,597Net increase in cash and cash equivalents313,9192,951,921Cash and cash equivalents, beginning of period33,5061,036,701	Investments in loans receivable	(9,939)		(359,683)		
Cash flows from financing activities:Net repayments under bank line of credit(454,000)Repayments of mortgage debt(10,057)(21,137)Issuance of senior unsecured notes450,0002,400,000Deferred financing costs(10,117)(42,852)Net proceeds from the issuance of common stock and exercise of options397,5691,248,049Dividends paid on common and preferred stock(211,067)(184,209)Issuance (purchase) of noncontrolling interests181(18,587)Distributions to noncontrolling interests(3,912)(3,667)Net cash provided by financing activities158,5973,377,597Net increase in cash and cash equivalents313,9192,951,921Cash and cash equivalents, beginning of period33,5061,036,701	Increase in restricted cash	(3,905)		(5,738)		
Net repayments under bank line of credit(454,000)Repayments of mortgage debt(10,057)(21,137)Issuance of senior unsecured notes450,0002,400,000Deferred financing costs(10,117)(42,852)Net proceeds from the issuance of common stock and exercise of options397,5691,248,049Dividends paid on common and preferred stock(211,067)(184,209)Issuance (purchase) of noncontrolling interests181(18,587)Distributions to noncontrolling interests(3,912)(3,667)Net cash provided by financing activities158,5973,377,597Net increase in cash and cash equivalents313,9192,951,921Cash and cash equivalents, beginning of period33,5061,036,701	Net cash used in investing activities	(31,146)		(575,503)		
Net repayments under bank line of credit(454,000)Repayments of mortgage debt(10,057)(21,137)Issuance of senior unsecured notes450,0002,400,000Deferred financing costs(10,117)(42,852)Net proceeds from the issuance of common stock and exercise of options397,5691,248,049Dividends paid on common and preferred stock(211,067)(184,209)Issuance (purchase) of noncontrolling interests181(18,587)Distributions to noncontrolling interests(3,912)(3,667)Net cash provided by financing activities158,5973,377,597Net increase in cash and cash equivalents313,9192,951,921Cash and cash equivalents, beginning of period33,5061,036,701	Cash flows from financing activities:					
Issuance of senior unsecured notes450,0002,400,000Deferred financing costs(10,117)(42,852)Net proceeds from the issuance of common stock and exercise of options397,5691,248,049Dividends paid on common and preferred stock(211,067)(184,209)Issuance (purchase) of noncontrolling interests181(18,587)Distributions to noncontrolling interests(3,912)(3,667)Net cash provided by financing activities158,5973,377,597Net increase in cash and cash equivalents313,9192,951,921Cash and cash equivalents, beginning of period33,5061,036,701		(454,000)				
Deferred financing costs(10,117)(42,852)Net proceeds from the issuance of common stock and exercise of options397,5691,248,049Dividends paid on common and preferred stock(211,067)(184,209)Issuance (purchase) of noncontrolling interests181(18,587)Distributions to noncontrolling interests(3,912)(3,667)Net cash provided by financing activities158,5973,377,597Net increase in cash and cash equivalents313,9192,951,921Cash and cash equivalents, beginning of period33,5061,036,701	Repayments of mortgage debt	(10,057)		(21,137)		
Net proceeds from the issuance of common stock and exercise of options397,5691,248,049Dividends paid on common and preferred stock(211,067)(184,209)Issuance (purchase) of noncontrolling interests181(18,587)Distributions to noncontrolling interests(3,912)(3,667)Net cash provided by financing activities158,5973,377,597Net increase in cash and cash equivalents313,9192,951,921Cash and cash equivalents, beginning of period33,5061,036,701		450,000		2,400,000		
Net proceeds from the issuance of common stock and exercise of options397,5691,248,049Dividends paid on common and preferred stock(211,067)(184,209)Issuance (purchase) of noncontrolling interests181(18,587)Distributions to noncontrolling interests(3,912)(3,667)Net cash provided by financing activities158,5973,377,597Net increase in cash and cash equivalents313,9192,951,921Cash and cash equivalents, beginning of period33,5061,036,701	Deferred financing costs	(10, 117)		(42,852)		
Dividends paid on common and preferred stock(211,067)(184,209)Issuance (purchase) of noncontrolling interests181(18,587)Distributions to noncontrolling interests(3,912)(3,667)Net cash provided by financing activities158,5973,377,597Net increase in cash and cash equivalents313,9192,951,921Cash and cash equivalents, beginning of period33,5061,036,701	Net proceeds from the issuance of common stock and exercise of options			1,248,049		
Issuance (purchase) of noncontrolling interests181(18,587)Distributions to noncontrolling interests(3,912)(3,667)Net cash provided by financing activities158,5973,377,597Net increase in cash and cash equivalents313,9192,951,921Cash and cash equivalents, beginning of period33,5061,036,701		(211,067)		(184,209)		
Distributions to noncontrolling interests(3,912)(3,667)Net cash provided by financing activities158,5973,377,597Net increase in cash and cash equivalents313,9192,951,921Cash and cash equivalents, beginning of period33,5061,036,701		181		(18,587)		
Net cash provided by financing activities158,5973,377,597Net increase in cash and cash equivalents313,9192,951,921Cash and cash equivalents, beginning of period33,5061,036,701		(3,912)		(3,667)		
Net increase in cash and cash equivalents313,9192,951,921Cash and cash equivalents, beginning of period33,5061,036,701						
Cash and cash equivalents, beginning of period33,5061,036,701						
		\$ 347,425	\$			

See accompanying Notes to Condensed Consolidated Financial Statements.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(1) Business

HCP, Inc., an S&P 500 company, together with its consolidated entities (collectively, HCP or the Company), invests primarily in real estate serving the healthcare industry in the United States (U.S.). The Company is a self-administered, Maryland real estate investment trust (REIT) organized in 1985. The Company is headquartered in Long Beach, California, with offices in Nashville, Tennessee and San Francisco, California. The Company acquires, develops, leases, manages and disposes of healthcare real estate, and provides financing to healthcare providers. The Company s portfolio is comprised of investments in the following five healthcare segments: (i) senior housing,
(ii) post-acute/skilled nursing, (iii) life science, (iv) medical office and (v) hospital. The Company makes investments within the healthcare segments using the following five investment products: (i) properties under lease, (ii) debt investments, (iii) developments and redevelopments, (iv) investment management and (v) RIDEA, which represents investments in senior housing operations utilizing the structure permitted by the Housing and Economic Recovery Act of 2008.

(2) Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. Management is required to make estimates and assumptions in the preparation of financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from management s estimates.

The condensed consolidated financial statements include the accounts of HCP, its wholly-owned subsidiaries and joint ventures or variable interest entities (VIEs) that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company s financial position, results of operations and cash flows have been included. Operating results for the three months ended March 31, 2012 are not necessarily indicative of the results that may be expected for the year ending December 31, 2012. The accompanying unaudited interim financial information should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2011 included in the Company s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC).

Certain amounts in the Company s condensed consolidated financial statements have been reclassified for prior periods to conform to the current period presentation. Assets sold or held for sale and associated liabilities have been reclassified on the condensed consolidated balance sheets

and the related operating results reclassified from continuing to discontinued operations on the condensed consolidated income statements (see Note 5). Facility-level revenues from 21 senior housing communities that are in a RIDEA structure are presented in resident fees and services on the condensed consolidated income statements; all facility-level resident fee and service revenue previously reported in rental and related revenues has been reclassified to resident fees and services (see Note 12 for additional information regarding the 21 RIDEA facilities).

Recent Accounting Pronouncements

In May 2011, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2011-04, *Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs* (ASU 2011-04). The amendments in this update result in additional fair value measurement and disclosure requirements within U.S. GAAP and International Financial Reporting Standards. Consequently, the amendments change the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. The adoption of ASU 2011-04 on January 1, 2012 did not have an impact on the Company s consolidated financial position or results of operations.

In June 2011, the FASB issued Accounting Standards Update No. 2011-05, *Presentation of Comprehensive Income* (ASU 2011-05). The amendments require that all non-owner changes in stockholders equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In the two-statement approach, the first statement should present total net income and its components followed consecutively by a second statement that should present total other comprehensive income, the components of other comprehensive income and the total of comprehensive income. In December 2011, the FASB deferred portions of this update in its issuance of Accounting Standards Update No. 2011-12 (see discussion below). The Company has elected the two-statement approach and the required financial statements are presented herein.

⁸

Table of Contents

In December 2011, the FASB issued Accounting Standards Update No. 2011-12, *Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05* to defer indefinitely the requirement of ASU 2011-05 to present on the face of the financial statements the effects of reclassifications out of accumulated other comprehensive income on the components of net income and other comprehensive income for all periods presented.

(3) HCR ManorCare Acquisition

On April 7, 2011, the Company completed its acquisition of substantially all of the real estate assets of HCR ManorCare, Inc. (HCR ManorCare), for a purchase price of \$6 billion (HCR ManorCare Acquisition). The purchase price consisted of the following: (i) \$4 billion in cash consideration; and (ii) \$2 billion representing the fair value of the Company s former HCR ManorCare debt investments that were settled as part of this acquisition. Through this transaction, the Company acquired 334 HCR ManorCare post-acute, skilled nursing and assisted living facilities. The facilities are located in 30 states, with the highest concentrations in Ohio, Pennsylvania, Florida, Illinois and Michigan. A wholly-owned subsidiary of HCR ManorCare operates the assets pursuant to a long-term triple-net master lease agreement supported by a guaranty from HCR ManorCare. Additionally, the Company exercised its option to purchase an ownership interest in HCR ManorCare for \$95 million that represented a 9.9% equity interest at closing.

The total purchase price of the HCR ManorCare Acquisition follows (in thousands):

Payment of aggregate cash consideration, net of cash acquired	\$ 3,801,624
HCP s loan investments in HCR ManorCare s debt settled at fair value(1)	1,990,406
Assumed HCR ManorCare accrued liabilities at fair value(2)	224,932
Total purchase consideration	\$ 6,016,962
Legal, accounting and other fees and costs(3)	\$ 26,839

(1) At closing, the Company recognized a gain of approximately \$23 million, included in interest income, which represents the fair value of the Company s existing mezzanine and mortgage loan investments in HCR ManorCare in excess of its carrying value on the acquisition date.

(2) In August 2011, the Company paid these amounts to certain taxing authorities or the seller.

The following table summarizes the fair value of the HCR ManorCare assets acquired and liabilities assumed at the April 7, 2011 acquisition date (in thousands):

\$

⁽³⁾ Represents estimated fees and costs of \$15.5 million (general and administrative) and the write-off of unamortized bridge loan fees of \$11.3 million (interest expense) upon its termination that were expensed in 2010 and 2011, respectively. These charges are directly attributable to the transaction and represent non-recurring costs.

Cash and cash equivalents	6,996
Intangible assets, net	14,888
Total assets acquired	6,023,958
Total liabilities assumed	224,932
Net assets acquired	\$ 5,799,026

In connection with the HCR ManorCare Acquisition, the Company entered into a credit agreement for a 365-day bridge loan facility (from funding to maturity) in an aggregate amount of up to \$3.3 billion, which was terminated in accordance with its terms in March 2011.

The assets and liabilities of the Company s investments related to HCR ManorCare and the related results of operations are included in the condensed consolidated financial statements from the April 7, 2011 acquisition date. For the three months ended March 31, 2012, the Company recognized revenues and earnings from its investments related to HCR ManorCare of \$142 million and \$155 million, respectively. See Note 8 for additional information regarding the Company s investment related to HCR ManorCare.

Table of Contents

Pro Forma Results of Operations

The following unaudited pro forma consolidated results of operations assume that the HCR ManorCare Acquisition, including the Company s equity interest in HCR ManorCare, was completed as of January 1, 2011 (in thousands, except per share amounts):

		Three Months	
		Ended	
	Mar		
Revenues	\$	442,166	
Net income		193,359	
Net income applicable to HCP, Inc.		189,468	
Basic earnings per common share	\$	0.46	
Diluted earnings per common share		0.46	

(4) Other Real Estate Property Investments

During the three months ended March 31, 2012, the Company funded an aggregate of \$30 million for construction, tenant and other capital improvement projects, primarily in its life science and medical office segments.

A summary of real estate acquisitions for the three months ended March 31, 2011 follows (in thousands):

			sideration		Assets A	cquired				
				Debt	D	ownREIT				Net
Segment	Ca	ash Paid	A	Assumed	ا	Units(1)	R	eal Estate	In	tangibles
Life science	\$	19,147	\$	48,252	\$		\$	61,710	\$	5,689
Medical office		29,743				1,500		26,191		5,052
	\$	48,890	\$	48,252	\$	1,500	\$	87,901	\$	10,741

(1) Non-managing member limited liability company units.

See discussion of the January 2011 purchase and consolidation of HCP Ventures II in Note 8.

During the three months ended March 31, 2011, the Company funded an aggregate of \$22 million for construction, tenant and other capital improvement projects, primarily in its life science and medical office segments. During the three months ended March 31, 2011, two of the Company s life science facilities located in South San Francisco were placed in service representing 88,000 square feet.

(5) Dispositions of Real Estate and Discontinued Operations

During the three months ended March 31, 2012, the Company sold a medical office building for \$7 million.

The following table summarizes operating income from discontinued operations (dollars in thousands):

		rch 31, 2011	· ·		
Rental and related revenues	\$	246	\$		577
Depreciation and amortization expenses		35			238
Operating expenses		2			1
Other (income) expense, net		72			(3)
Income, net of income taxes	\$	137	\$		341
Gain on sales of real estate, net of income taxes	\$	2,856	\$		
Number of properties held for sale					4
Number of properties sold		1			
Number of properties included in discontinued operations		1			4

Table of Contents

(6) Net Investment in Direct Financing Leases

On April 7, 2011, the Company completed the acquisition of 334 HCR ManorCare properties subject to a single master lease that the Company classified as a direct financing lease (DFL). See discussion of the HCR ManorCare Acquisition in Note 3.

The components of net investment in DFLs consisted of the following (dollars in thousands):

	March 31, 2012	December 31, 2011
Minimum lease payments receivable(1)	\$ 25,615,872	\$ 25,744,161
Estimated residual values	4,010,514	4,010,514
Less unearned income	(22,858,275)	(23,026,898)
Net investment in direct financing leases	\$ 6,768,111	\$ 6,727,777
Properties subject to direct financing leases	361	361

(1) The minimum lease payments receivable are primarily attributable to HCR ManorCare (\$24.4 billion and \$24.5 billion at March 31, 2012 and December 31, 2011, respectively). The triple-net master lease with HCR ManorCare provides for rent in the first year of \$473 million (\$489 million beginning April 1, 2012). The rent increases by 3.5% per year after each of the first five years and by 3% for the remaining portion of the initial lease term. The properties are grouped into four pools, and HCR ManorCare has a one-time extension option for each pool with rent increased for the first year of the extension option to the greater of fair market rent or a 3% increase over the rent for the prior year. Including the extension options, which the Company determined to be bargain renewal options, the four leased pools had total initial available terms ranging from 23 to 35 years.

Certain of the non-HCR ManorCare leases contain provisions that allow the tenants to elect to purchase the properties during or at the end of the lease terms for the aggregate initial investment amount plus adjustments, if any, as defined in the lease agreements. Certain leases also permit the Company to require the tenants to purchase the properties at the end of the lease terms.

(7) Loans Receivable

The following table summarizes the Company s loans receivable (in thousands):

	Real Estate Secured	March 3 Oth Secu		Total	D Estate 1red	ecember 31, 201 Other Secured	1	Total
Mezzanine	\$	\$	83,710	\$ 83,710	\$:	\$ 90,148	\$	90,148
Other	45,517			45,517	35,643			35,643
Unamortized discounts, fees								
and costs	(783)		(1,088)	(1,871)	(1,040)	(1,088)	(2,128)
Allowance for loan losses		((13,410)	(13,410)		(13,410)	(13,410)

\$ 44,734	\$ 69,212	\$ 113,946 \$	34,603	\$ 75,650	\$ 110,253

Delphis Operations, L.P. Loan

The Company holds a secured term loan made to Delphis Operations, L.P. (Delphis or the Borrower) that is collateralized by all of the assets of the Borrower, which collateral is comprised primarily of interests in partnerships operating surgical facilities, some of which are on the premises of properties owned by the Company or HCP Ventures IV, LLC, an unconsolidated joint venture of the Company. In December 2009, the Company determined that the loan was impaired and recognized a provision for loan loss (impairment) of \$4.3 million. In January 2011, the Company placed the loan on cost-recovery status, whereby accrual of interest income was suspended and any payments received from the Borrower are applied to reduce the recorded investment in the loan. In September 2011, the Company determined that the fair value of the collateral assets was no longer in excess of the carrying value of the loan and therefore recognized an additional provision for losses of \$15.4 million.

As part of a March 2012 agreement (the 2012 Agreement) between Delphis, certain past and current principals of Delphis and the Cirrus Group, LLC (the Guarantors) and the Company, the Company agreed, among other things, to allow the distribution of \$1.5 million to certain of the Guarantors from funds generated from sales of assets that were pledged as additional collateral for this loan. In consideration of this distribution, among other things, the Company received cash of \$4.5 million (including funds that had been escrowed from past sales of the Guarantors collateral) and the assignment of certain rights to general and limited partnership interests (including the release of claims by such entities). Further, the Company, as part of the 2012 Agreement, agreed to provide financial incentives to the Borrower regarding the liquidation of the primary collateral assets for this loan.

Table of Contents

The Company valued the cash payments and other consideration received through the 2012 Agreement (after reducing the consideration by \$0.5 million for related legal expenses) at \$6.5 million, which the Company applied to the carrying value of the loan, reducing the balance to \$69.2 million as of March 31, 2012 from its balance of \$75.7 million as of December 31, 2011. During the three months ended March 31 2011, the Company received cash payments from the Borrower of \$1.0 million. At March 31, 2012, the Company believes that the fair value of the collateral supporting this loan is in excess of the loan s carrying value.

HCR ManorCare Loans

In December 2007, the Company made a \$900 million investment (at a discount of \$100 million) in HCR ManorCare mezzanine loans, which paid interest at a floating rate of one-month London Interbank Offered Rate (LIBOR) plus 4.0%. Also, in August 2009 and January 2011, the Company purchased \$720 million (at a discount of \$130 million) and \$360 million, respectively, in participations in HCR ManorCare first mortgage debt, which paid interest at LIBOR plus 1.25%.

On April 7, 2011, upon closing of the HCR ManorCare Acquisition, the Company s loans to HCR ManorCare were settled, which resulted in additional interest income of \$23 million, which represents the excess of the loans fair values above their carrying values at the acquisition date. See Note 3 for additional discussion related to the HCR ManorCare Acquisition.

Genesis HealthCare Loans

In September and October 2010, the Company purchased participations in a senior loan and mezzanine note of Genesis HealthCare (Genesis) with par values of \$278 million (at a discount of \$28 million) and \$50 million (at a discount of \$10 million), respectively. The Genesis senior loan paid interest at LIBOR (subject to a floor of 1.5%, increasing to 2.5% by maturity) plus a spread of 4.75%, increasing to 5.75% by maturity. The senior loan was secured by all of Genesis assets. The mezzanine note paid interest at LIBOR plus a spread of 7.50%. In addition to the coupon interest payments, the mezzanine note required the payment of a termination fee, of which the Company s share prior to the early repayment of this loan was \$2.3 million.

On April 1, 2011, the Company received \$330.4 million from the early repayment of its loans to Genesis, and recognized additional interest income of \$34.8 million, which represents the related unamortized discounts and termination fee.

(8) Investments in and Advances to Unconsolidated Joint Ventures

HCP Ventures II

On January 14, 2011, the Company acquired its partner s 65% interest in HCP Ventures II, a joint venture that owned 25 senior housing facilities, becoming the sole owner of the portfolio.

The purchase consideration of HCP Ventures II follows (in thousands):

Cash paid for HCP Ventures II s partnership interest	\$ 135,550
Fair value of HCP s 35% interest in HCP Ventures II (carrying value of \$65,223 at closing)(1)	72,992
Total consideration	\$ 208,542
Estimated fees and costs	
Legal, accounting and other fees and costs(2)	\$ 150
Debt assumption fees(3)	500